<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912949</url>
  </required_header>
  <id_info>
    <org_study_id>MCLA-128-CL01</org_study_id>
    <secondary_id>2014-003277-42</secondary_id>
    <nct_id>NCT02912949</nct_id>
  </id_info>
  <brief_title>A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion</brief_title>
  <official_title>A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merus N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merus N.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent
      study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of
      zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design :

      This open label (all participants know the identity of the study drug), multicenter (more
      than one study site), first-in-human study consisting of 2 parts. Part 1 is a dose escalation
      and Part 2 is a dose expansion cohort. Part 1 has been completed.

      Part 2 new patient populations examined:

        -  Group F: Patients with NSCLC with documented NRG1 fusion

        -  Group G: Patients with pancreatic cancer with documented NRG1 fusion

        -  Group H: Patients with any other solid tumor with documented NRG1 fusion

      For these new patient populations, Part 2 will further characterize the safety and
      tolerability of the selected dose level of zenocutuzumab (MCLA-128), as well as assessment of
      CBR, defined as the proportion of patients with a CR, PR or durable SD (SD for at least 12
      weeks in duration). For the new patient populations, overall response rate (ORR) and duration
      of response (DOR) will be described.

      The study consists of 3 periods: Screening period (up to 28 days prior to the first dose of
      study drug); Treatment period (treatment cycles of 28 days); and Follow Up period (through 30
      days after the last dose and quarterly checks for survival data for up to 2 years).
      Participants' safety will be monitored throughout the study.

      Number of Sites:

      Up to 40 sites are estimated to be involved during Parts 1 and 2 of the study. Additional
      sites may be added to ensure there is an acceptable enrollment rate or to replace
      non-enrolling/withdrawn sites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety and tolerability of zenocutuzumab (MCLA-128)</measure>
    <time_frame>6-12 months</time_frame>
    <description>Number of participants with Adverse Events (AE) and Serious Adverse Events (SAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective overall response rate (ORR)</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluation of clinical benefit assessed by RECIST v1.1 determining objective overall response rate (ORR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluation of clinical benefit assessed by RECIST v1.1 determining duration of response (DOR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of anti-tumor activity and biomarkers</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate the correlation between the anti-tumor activity of zenocutuzumab (MCLA-128) and HER2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of anti-tumor activity and biomarkers</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate the correlation between the anti-tumor activity of zenocutuzumab (MCLA-128) and HER3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of anti-tumor activity and biomarkers</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate the correlation between the anti-tumor activity of zenocutuzumab (MCLA-128) and Heregulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of anti-tumor activity and biomarkers</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate the correlation between the anti-tumor activity of zenocutuzumab (MCLA-128) and disease related biomarkers (i.e. CA19-9)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE [safety and tolerability]</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate severity, frequency and duration of Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration [Cmax]</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the Cmax of zenocutuzumab (MCLA-128)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution [V]</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the volume of distribution of zenocutuzumab (MCLA-128)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state [Vss]</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the volume of distribution of zenocutuzumab (MCLA-128) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life [t1/2]</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the half-life of zenocutuzumab (MCLA-128)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time zero to time t [AUC0-t]</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the Area under the concentration versus time curve from time zero to time t [AUC0-t] of zenocutuzumab (MCLA-128)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration versus time curve [AUC0-∞]</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the area under the concentration versus time curve [AUC0-∞] of zenocutuzumab (MCLA-128)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach maximum concentration [tmax]</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the time to reach maximum concentration [tmax] of zenocutuzumab (MCLA-128)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies against zenocutuzumab (MCLA-128)</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the Incidence of anti-drug antibodies against zenocutuzumab (MCLA-128)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum titers of anti-drug antibodies</measure>
    <time_frame>36 months</time_frame>
    <description>Assess serum titers of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor response of zenocutuzumab (MCLA-128) by RECIST v1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Assess the anti-tumor response of zenocutuzumab (MCLA-128) by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) of zenocutuzumab (MCLA-128)</measure>
    <time_frame>36 months</time_frame>
    <description>CBR assessed as the proportion of patients in whom a complete response (CR) or partial response (PR) or stable disease (SD) is observed (where SD duration is a minimum of 12 weeks) by RECIST v1.1 .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) and survival</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluation of clinical benefit assessed by RECIST v1.1 determining objective progression-free survival (PFS) and/or survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Solid Tumours Harboring NRG1 Fusion</condition>
  <condition>NSCLC Harboring NRG1 Fusion</condition>
  <condition>Pancreatic Cancer Harboring NRG1 Fusion</condition>
  <condition>NRG1 Fusion</condition>
  <arm_group>
    <arm_group_label>Part 2 Pancreatic cancer harboring NRG1 fusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 NSCLC cancer harboring NRG1 fusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Solid tumour (basket) harboring NRG1 fusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zenocutuzumab (MCLA-128)</intervention_name>
    <description>full length IgG1 bispecific antibody targeting HER2 and HER3</description>
    <arm_group_label>Part 2 NSCLC cancer harboring NRG1 fusion</arm_group_label>
    <arm_group_label>Part 2 Pancreatic cancer harboring NRG1 fusion</arm_group_label>
    <arm_group_label>Part 2 Solid tumour (basket) harboring NRG1 fusion</arm_group_label>
    <other_name>bispecific</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one measurable lesion according to RECIST v1.1 OR evaluable disease for a
             limited number of patients (up to 10) in Group H;

          -  Performance status of ECOG 0 or 1;

          -  Estimated life expectancy of at least 12 weeks;

          -  Toxicities incurred as a result of previous anti-cancer therapy resolved to ≤Grade 1;

          -  Treatment with anti-cancer medication or investigational drugs within the following
             intervals before the first dose of MCLA-128:

               1. &gt;14 days or &gt;5 half-lives prior to study entry, whichever is shorter.

               2. &gt;14 days for radiotherapy.

          -  Recovery from major surgery or other complication to ≤ Grade 2 or baseline ;

          -  Absolute neutrophil count ≥1.5 x 109/L without colony stimulating factor support;

          -  Platelets ≥100 x 109/L;

          -  Hemoglobin ≥8 g/dL or ≥2.2 mmol/L;

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤3 x upper limit of
             normal (ULN) and total bilirubin ≤1.5 x ULN; in cases of metastatic liver involvement,
             ALT/AST ≤5 x ULN and total bilirubin ≤2 x ULN will be allowed; in cases of antecedents
             of Gilbert's syndrome when total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN
             will be allowed;

          -  Estimated glomerular filtration rate (GFR) of &gt;30 mL/min

          -  Able to provide a tumor biopsy sample (fresh strongly preferred or else archival);

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 6 month after
             completion of study therapy;

          -  Patients must have received prior standard therapy appropriate for their tumor type
             and stage of disease, or in the opinion of the Investigator, would be unlikely to
             tolerate or derive clinically meaningful benefit from appropriate standard of care
             therapy;

          -  Locally-advanced unresectable or metastatic solid tumor malignancy with documented
             NRG1 gene fusion, identified through molecular assays such as PCR, next generation
             sequencing-based assays [DNA or RNA], or FISH as routinely performed at CLIA or other
             similarly-certified laboratories.

        Exclusion Criteria:

          -  Pregnant or lactating;

          -  Presence of an active uncontrolled infection or an unexplained fever;

          -  Known hypersensitivity to any of the components of MCLA-128;

          -  Known HIV, active Hepatitis B or Hepatitis C; patients treated for Hepatitis C and
             have undetectable viral loads are eligible

          -  Known symptomatic or unstable brain metastases;

          -  Patients with leptomeningeal metastases

          -  Presence of congestive heart failure or Left Ventricular Ejection Fraction&lt;50% or
             history of significant cardiac disease, unstable angina, myocardial infarction or
             ventricular arrhythmia requiring medication.

          -  Previous or concurrent malignancy (excluding non-basal cell carcinoma of skin or
             carcinoma in situ of the uterine cervix) unless the tumor was treated with curative
             intent more than 2 years prior to study entry;

          -  Presence of any other medical or psychological condition deemed by the Investigator to
             be likely to interfere with a patient's ability to sign informed consent, cooperate or
             participate in the study, or interfere with the interpretation of the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Schram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merus Inquiries</last_name>
    <phone>1-833-NRG-1234</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trials referrals office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii-Saab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignatius Ou, MD</last_name>
      <phone>877-827-8839</phone>
    </contact>
    <investigator>
      <last_name>Ignatius Ou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivaani Kummar, MD</last_name>
      <phone>877-827-8839</phone>
    </contact>
    <investigator>
      <last_name>Shivaani Kummar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Liu, MD</last_name>
      <phone>202-687-9861</phone>
    </contact>
    <investigator>
      <last_name>Stephen Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trials referral office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Jason Starr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cleary, MD</last_name>
      <phone>617-632-6623</phone>
    </contact>
    <investigator>
      <last_name>James Cleary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Ventimiglia</last_name>
      <phone>313-576-9813</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trials referral office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Wen Wee Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Schram, MD</last_name>
      <phone>646-888-4226</phone>
    </contact>
    <investigator>
      <last_name>Alison Schram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Rodon, MD</last_name>
      <phone>713-563-1930</phone>
    </contact>
    <investigator>
      <last_name>Jordi Rodon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Sandefur</last_name>
      <phone>253-380-5299</phone>
      <email>ssandefur@nwmsonline.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess MargaretCancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grainne O'Kane, MD</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4853</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Louis Pradel, FR</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaele Duruisseaux, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michaele Duruisseaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Zedouard</last_name>
    </contact>
    <investigator>
      <last_name>Andreea Varga, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niguarda Cancer Centre</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Siena, Prof</last_name>
    </contact>
    <contact_backup>
      <last_name>Giovanna Marrapese</last_name>
    </contact_backup>
    <investigator>
      <last_name>Salvatore Siena, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Dong-Wan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kim Dong-Wan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NKI</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frans Opdam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellis van Liempt</last_name>
      <phone>+31887569057</phone>
      <email>oncology-trialssecretariat@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Els Witteveen, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Oslo</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tormod Guren, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre of Singapore PTE LTD</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Shao Weng, MD</last_name>
    </contact>
    <investigator>
      <last_name>Justina Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall D'Hebron Institute of Oncology (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabet Tebe</last_name>
      <email>hclinicaltrials@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Alsina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Hospital Fundación Jiménez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Armellini</last_name>
    </contact>
    <investigator>
      <last_name>Victor Moreno, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Ordoñez</last_name>
    </contact>
    <investigator>
      <last_name>Valentina Boni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Paz-Ares, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Paz-Ares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital 7</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Yang Chih-Hsin, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Yang Chih-Hsin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
    <country>Portugal</country>
  </removed_countries>
  <link>
    <url>http://www.nrg1.com</url>
    <description>For more information about MCLA-128 and the MCLA-128-CL01 study</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bispecific Antibody IgG1, HER2, HER3</keyword>
  <keyword>MCLA-128</keyword>
  <keyword>Antibodies, Bispecific</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>NRG1 fusion</keyword>
  <keyword>NRG1</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>PDAC</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>zenocutuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

